WPRIM Management System> DCMS> Journal of Lipid and Atherosclerosis> 2019> 8> 2

Volume: 8 Issue: 2

1. Mendelian Randomization Analysis in Observational Epidemiology Page:67—77
2. 2018 Guidelines for the Management of Dyslipidemia in Korea Page:78—131
3. Genetically Mediated Lipid Metabolism and Risk of Insulin Resistance: Insights from Mendelian Randomization Studies Page:132—143
4. Diabetes-related Amylin Dyshomeostasis: a Contributing Factor to Cerebrovascular Pathology and Dementia Page:144—151
5. Single Cell RNA-Sequencing for the Study of Atherosclerosis Page:152—161
6. Aspirin for Primary Prevention of Cardiovascular Disease Page:162—172
7. The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers Page:173—182
8. Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors Page:183—191
9. Nutritional Therapy for Asian Patients at Risk for Atherosclerotic Cardiovascular Disease Page:192—203
10. Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels? Page:204—207
11. Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol Page:208—220
12. Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: a Randomized Controlled Trial Page:221—231
13. Analysis of ¹⁸F-Fluorodeoxyglucose and ¹⁸F-Fluoride Positron Emission Tomography in Korean Stroke Patients with Carotid Atherosclerosis Page:232—241
14. Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea Page:242—251
15. Effects of Obesity and Family History of Diabetes on the Association of CETP rs6499861 with HDL-C Level in Korean Populations Page:252—257
16. Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea Page:258—266
17. Anti-malarial Drugs Reduce Vascular Smooth Muscle Cell Proliferation via Activation of AMPK and Inhibition of Smad3 Signaling Page:267—276